On October 3, 2025, XOMA Royalty Corporation announced that it has extended the expiration of its tender offer to purchase all outstanding shares of LAVA Therapeutics N.V. The new deadline is 11:59 p.m. Eastern Time on October 17, 2025, giving LAVA shareholders an additional two weeks to tender their shares.
Under the terms of the offer, XOMA will pay a cash amount to be determined in accordance with the purchase agreement, plus a non‑transferable contingent value right (CVR) per share that entitles holders to 75% of the net proceeds from LAVA’s two partnered assets and 75% of any net proceeds from out‑licensing or sale of LAVA’s unpartnered programs. LAVA shareholders who have already tendered their shares are not required to re‑tender, and the offer is expected to close in the fourth quarter of 2025 pending customary closing conditions.
The extension provides XOMA with additional time to secure the necessary shareholdings and allows LAVA shareholders to benefit from the proposed acquisition terms. The transaction is anticipated to result in a corporate reorganization that will see XOMA acquire 100% of the shares in LAVA’s successor, with LAVA shareholders receiving the same cash and CVR consideration as outlined in the tender offer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.